Board and CEO

Mr Adrian Cosenza is the Chair of the Australia and New Zealand Sarcoma Association. He is also the current CEO of the Australian Orthopaedic Association (AOA), having joined AOA in July 2010. Under his leadership, Adrian has led the modernisation of AOA into a vibrant and respected leader in the field of orthopaedics. Today, the AOA is a major global benchmark for its orthopaedic surgical and education program as well as addressing leading aspirations in research, ethics and professionalism.

Adrian is an experienced CEO and seasoned director, having served in an executive capacity in three industries including medical education, technology and banking and finance. He is the current CEO of AOA Research Foundation, the first national CEO CookOff Brand Ambassador for OzHarvest, current Chair of the Australian Consensus Framework for Ethical Collaboration in the Healthcare sector, and is the Australasian Ambassador for the International Medical Education Leaders Forum serving on the Global Planning committee. Adrian has served on the Board of 14 companies covering four industries in four different international jurisdictions. He has three degrees including a Master of Business Administration from the global-leading IMD in Lausanne, Switzerland, and a Masters of Commerce. He is also Fellow of three professional bodies covering governance, financial services and accounting.

Adrian’s passion is to create an environment for people to perform to the best of their abilities and assist organisations in achieving excellent outcomes.

Prof Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.

As a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.

Prof Angela is the co-Chair of ANZSA’s Scientific Advisory Committee.

Dr Denise Caruso has been leading ANZSA for over 10 years.

She holds a PhD in Immunology from the University of Texas/MD Anderson Cancer Center, where she was a National Institutes of Health (USA) Fellow in Tumour Immunology and has been at the forefront of immunotherapy for solid tumours research.

Prior to commencing her graduate studies, Denise held research roles at Harvard Medical School, Boston and at the Fred Hutchinson Cancer Research Centre in Seattle. Her previous role was as Senior Research Fellow at the Murdoch Children’s Research Institute at the Children’s Cancer Center at the Royal Children’s Hospital Melbourne, where she conducted immunotherapy clinical trials and basic science research.

Denise is also a Member of the Australian Institute of Company Directors.

Prof David Gyorki is a specialist surgical oncologist at the Peter MacCallum Cancer Centre with a particular interest in the management of patients with soft tissue sarcoma and melanoma. Prof Gyorki is an active member of the Transatlantic and Australasian Retroperitoneal Sarcoma Working Group and is actively involved in a large registry of patients with this cancer to better understand the disease and the best way to optimise treatment.

Prof Gyorki is also involved in translational research in tumour immunology and is particularly interested in understanding the role of novel immunotherapy agents to reduce the risk of recurrence for patients having surgery for cancer.  He serves as the ASCO Systemic Therapy for Melanoma Guidelines Working Group and is the Chair of the governance committee of the international retroperitoneal sarcoma registry.

A/Prof Peter Steadman is an orthopaedic surgeon with special interests in upper and lower limb general orthopaedics, arthroplasty and bone sarcoma. Since becoming a Fellow of the Royal Australian College of Surgeons in 1995, he became an A/Prof at University of Queensland in 2008 and has been a specialist practicing in both public and private hospitals. He was also a Federal Director of the Australian Orthopaedic Association (AOA) governing board and national Treasurer.

A/Prof Peter was the founding member of the Australian Sarcoma Group before it merged with the Australasian Sarcoma Study Group to form ANZSA, in which he now serves as a Board member. He is also ANZSA’s Orthopaedic Chair in Australia.

Asscoiate Professor Wayne Nicholls is a paediatric and adolescent oncologist at the Queensland Children’s Hospital with over 20 years’ experience and holds a particular interest in brain tumours and sarcomas.

Wayne has been a member of ANZSA and an active contributor to the ANZSA Scientific Advisory Committee for several years before joining the Board of Directors. Wayne is also a member of the Consumer Advisory Panel. 

Clinical Prof. Fiona Maclean BAppSc, MBBS (Hons), FRCPA, GAICD graduated from the University of Sydney with First Class Honours. She initially worked as a resident medical officer at the Concord Repatriation General Hospital, where she was awarded Intern of the Year. Prof. Maclean holds the position of Clinical Professor in the Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University.

She has authored two chapters in the current edition of Sternberg’s Diagnostic Surgical Pathology, and one chapter in the current edition of Histology for Pathologists, both of which are premier textbooks in the fields of pathology and histology. She is President of the Australasian Division of the International Academy of Pathology (IAP). Prof. Maclean has special interests in urogenital and musculoskeletal pathology.

Ms. Sarah Cheung is a chartered accountant and serves as the chairperson of the Consumer Advisory panel. She first joined ANZSA as a consumer representative in April 2022, having been diagnosed with Retroperitoneal Liposarcoma in early 2021.  She is currently the only representative from NZ and resides in Auckland.

Sarah is passionate about raising Sarcoma awareness and helping to provide relevant and trustworthy information to patients, carers and survivors.  She also hopes that there is better equality and uniformity with the level of care provided to Sarcoma patients who come from indigenous, ethnic minority and regional backgrounds.

Outside of work, she enjoys watercolour painting and spending time with her family.

Dr Jason Cain, PhD, is the Research Group Head of the Developmental and Cancer Biology, and the Sarcoma Programs at the Hudson Institute of Medical Research. Jason is a developmental and cancer biologist involved in full time discovery and translational research for the last 17 years. He obtained his PhD from Monash University and undertook postdoctoral training at the Hospital for Sick Children, Toronto, Canada. Jason’s research focus is on understanding the roles of critical embryonic signalling pathways and epigenetic mechanisms in normal and abnormal development leading to childhood, adolescent and young adult cancers, including sarcomas.

Jason’s work has underpinned a Phase II clinical trial for the small molecule SMO inhibitor, sonidegib, in sarcoma and more recently a Phase II clinical trial for the histone deacetylase inhibitor, panobinostat in childhood osteosarcoma and malignant rhaboid tumours.

Dr Joanna Connor is a UK trained medical oncologist who relocated to  Auckland in 2019. She specialises in breast and sarcoma, and is clinical lead for sarcoma in medical oncology at Te Pūriri o Te Ora, Auckland Regional Cancer and Blood Service.  

As a current member of the ANZSA SAC committee, Joanna is passionate about improving sarcoma outcomes through research and healthcare networks. She has led a number of projects to improve sarcoma care in New Zealand, and has active experience of leadership for a non-profit organisation. As the New Zealand Director she looks forward to contributing to ANZSA’s future strategic direction with improvement of Australasian sarcoma care the forefront.

Dr Vivek Bhadri is a paediatric and adolescent medical oncologist based at Chris O’Brien Lifehouse and Westmead Hospital in Sydney. He is also the medical lead for the Adolescent and Young Adult (AYA) Youth Cancer Services at both sites with expertise in the management of younger sarcoma patients.

He is particularly passionate about access to clinical trials through national and international collaborations, and has facilitated links between paediatric and adult trial groups opening trials across the age spectrum. He has been a member of ANZSA since 2012 and of the ANZSA Scientific Advisory Committee since its inception, and with a deep understanding of the landscape of sarcoma care in Australia is well placed to contribute towards ANZSA’s strategic goals.

Andy is an Orthopaedic surgeon and orthopaedic oncologist at Auckland City Hospital, and Clinical Director of the North Island Sarcoma Service. Andy trained as an Orthopaedic surgeon in New Zealand before heading to London for Fellowship at the Royal National Orthopaedic Hospital (RNOH) and London Sarcoma Service (LSS). He stayed on as a consultant orthopaedic oncologist for 2 years before returning to New Zealand in 2019. His interests are in service improvement, improving patient outcomes and stimulating research in sarcoma

Richard Boyle is a Clinical Associate Professor and Senior Consultant Orthopaedic Surgeon with special interest in joint replacement, complex primary and revision arthroplasty, bone and soft tissue tumour surgery including sarcoma, and modern reconstructive techniques including 3D printing, navigation, biological and patient specific surgery.

He completed orthopaedic training in Sydney, followed by sub-specialist training at Royal Prince Alfred Hospital and internationally in Toronto, Edinburgh, Basel and Vienna.

A/Prof Boyle is Head of the NSW Bone and Soft Tissue Sarcoma Unit at Royal Prince Alfred Hospital, Chair of the Sarcoma MDT, Chair of the NSW Sarcoma Operational Management Committee, Fellow of the Australian Orthopaedic Association, AOA Chair of ANZSA Board, previously chair of the AOA Northside Board of Studies.

His professional memberships include ISOLS, APMSTS, ANZSA, and ASA, and is currently the Oceania Lead of the BOOM International Consensus Group. He also serves as a Board Member of the Cooper Rice Brading Foundation, Director of Orthopaedic Excellence Incorporated and Sarcoma Australia Foundation, and Medical Director of the NSW Rachel Foster Bone Bank. He holds academic appointments as Clinical Associate Professor at the University of Notre Dame Sydney and Senior
Lecturer at the University of Sydney.

Nationally and internationally recognised, A/Prof Boyle has authored numerous publications and presentations, and participates in clinical trials in tumour surgery and arthroplasty. He has been on a number of industry panels, as well as implant design teams. He co-created the Reconstructive Pelvic Anatomy classification system, as well as the Complex Orthopaedic Reconstructive and Sarcoma Surgical Outcomes Registry.

Overarching all his work however, he particularly values the multidisciplinary nature of tumour surgery and the privilege of caring for patients across all ages, from paediatric to adult.